Literature DB >> 31332073

Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis.

Aubrey Watson1, Jun Taek Oh1, Karen Sauve1, Patricia A Bradford2, Cara Cassino1, Raymond Schuch3.   

Abstract

Exebacase, a recombinantly produced lysin (cell wall hydrolase), and comparator antibiotics were tested by the broth microdilution method against strain sets of Staphylococcus and Streptococcus spp., which are the most common causes of infective endocarditis in humans. Exebacase was active against all Staphylococcus spp. tested, including S. aureus and coagulase-negative staphylococci (MIC50/90, 0.5/1 μg/ml). Activity against Streptococcus spp. was variable, with S. pyogenes, S. agalactiae, and S. dysgalactiae (MIC50/90, 1/2 μg/ml) among the most susceptible.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcuszzm321990; Streptococcuszzm321990; antimicrobial activity; exebacase; infective endocarditis; lysin

Year:  2019        PMID： 31332073      PMCID： PMC6761524          DOI： 10.1128/AAC.01078-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  39 in total

1.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Authors:  Michael A Pfaller; Robert K Flamm; Mariana Castanheira; Helio S Sader; Rodrigo E Mendes
Journal:  Int J Antimicrob Agents       Date:  2017-12-23       Impact factor: 5.283

Review 3.  Acute infective endocarditis.

Authors:  Jay R McDonald
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

Review 4.  Enterococcus faecalis infective endocarditis: focus on clinical aspects.

Authors:  Anders Dahl; Niels Eske Bruun
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-09

Review 5.  Current Hypotheses in Cardiac Surgery: Biofilm in Infective Endocarditis.

Authors:  Haytham Elgharably; Syed T Hussain; Nabin K Shrestha; Eugene H Blackstone; Gösta B Pettersson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2015-12-11

Review 6.  Infective Endocarditis.

Authors:  Elaine Yang; Bradley W Frazee
Journal:  Emerg Med Clin North Am       Date:  2018-11       Impact factor: 2.264

7.  Surgery for Infective Endocarditis: Outcomes and Predictors of Mortality in 360 Consecutive Patients.

Authors:  Mina Farag; Tobias Borst; Anton Sabashnikov; Mohamed Zeriouh; Bastian Schmack; Rawa Arif; Carsten J Beller; Aron-Frederik Popov; Klaus Kallenbach; Arjang Ruhparwar; Pascal M Dohmen; Gábor Szabó; Matthias Karck; Alexander Weymann
Journal:  Med Sci Monit       Date:  2017-07-25

8.  Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin.

Authors:  David M Bamberger
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

9.  Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.

Authors:  Raymond Schuch; Han M Lee; Brent C Schneider; Karen L Sauve; Christina Law; Babar K Khan; Jimmy A Rotolo; Yuki Horiuchi; Daniel E Couto; Assaf Raz; Vincent A Fischetti; David B Huang; Robert C Nowinski; Michael Wittekind
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226

10.  Spondylodiskitis and endocarditis due to Streptococcus gordonii.

Authors:  Ziv Dadon; Assaf Cohen; Yael M Szterenlicht; Marc V Assous; Yair Barzilay; David Raveh-Brawer; Amos M Yinnon; Gabriel Munter
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-10-04       Impact factor: 3.944
View more
  15 in total

1.  Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.

Authors:  Vance G Fowler; Anita F Das; Joy Lipka-Diamond; Raymond Schuch; Roger Pomerantz; Luis Jáuregui-Peredo; Adam Bressler; David Evans; Gregory J Moran; Mark E Rupp; Robert Wise; G Ralph Corey; Marcus Zervos; Pamela S Douglas; Cara Cassino
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.

Authors:  Dario Lehoux; Arnold S Bayer; Sonia U Shah; Yan Q Xiong; Wessam Abdelhady; James Iwaz; Youngju Pak; Raymond Schuch; Cara Cassino
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus.

Authors:  Aubrey Watson; Karen Sauve; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

4.  Heaping the Pelion of Vancomycin on the Ossa of Methicillin-resistant Staphylococcus aureus: Back to Basics in Clinical Care and Guidelines.

Authors:  William F Wright; Sarah C J Jorgensen; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

Review 5.  The Advantages and Challenges of Using Endolysins in a Clinical Setting.

Authors:  Ellen Murray; Lorraine A Draper; R Paul Ross; Colin Hill
Journal:  Viruses       Date:  2021-04-15       Impact factor: 5.048

Review 6.  Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection.

Authors:  Tristan Ferry; Camille Kolenda; Thomas Briot; Aubin Souche; Sébastien Lustig; Jérôme Josse; Cécile Batailler; Fabrice Pirot; Mathieu Medina; Gilles Leboucher; Frédéric Laurent
Journal:  Viruses       Date:  2021-12-02       Impact factor: 5.048

7.  Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity.

Authors:  Maria M Traczewski; Jane E Ambler; Raymond Schuch
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

8.  Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.

Authors:  Jun T Oh; Jane E Ambler; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

9.  Characterization of the Bacteriophage-Derived Endolysins PlySs2 and PlySs9 with In Vitro Lytic Activity against Bovine Mastitis Streptococcus uberis.

Authors:  Niels Vander Elst; Sara B Linden; Rob Lavigne; Evelyne Meyer; Yves Briers; Daniel C Nelson
Journal:  Antibiotics (Basel)       Date:  2020-09-19

10.  Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection.

Authors:  Steven M Swift; Karen Sauve; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.